Aurobindo Arm’s Facility In Rajasthan Gets 7 US FDA Observations

Hyderabad: Aurobindo Pharma, on Friday, May 3, said it has received seven observations from the United States Food and Drug Administration ( US FDA) for its unit-II formulation manufacturing facility located in Bhiwadi, Rajasthan.

The FDA conducted an inspection of the pharmaceutical company’s facility from April 25 to May 3, 2024. The US FDA has issued seven observations for the facility.

The facility is operated by Eugia Pharma Specialities Ltd, a wholly-owned subsidiary of Aurobindo Pharma. “The United States Food and Drug Administration (US FDA) inspected Unit-II, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly-owned subsidiary of the Company, situated at Bhiwadi, Alwar, Rajasthan, from April 25th to May 3rd 2024,” the company said in an exchange filing.

The observations from the FDA are procedural in nature, according to Aurobindo Pharma. In response to this development, the company said that it would address these observations within the stipulated time frame.

Earlier last month, the US FDA conducted an inspection of its newly-operational injectable facility in Andhra Pradesh and issued three observations.

The shares of the pharma company ended 0.8% in the red on Friday, May 3. The stock has gained 6.19% in 2024 so far and 87.27% in one year.

Related Posts

  • Pharma
  • July 16, 2025
  • 151 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 48 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Famous Vaidyaratnam Ayurveda Clinic in Delhi is now more Accessible to Patients

Famous Vaidyaratnam  Ayurveda  Clinic in Delhi is now more Accessible to Patients